Management of symptomatic<unk>  follows established treatment algorithms for myocardial infarction.Treatment options include: * emergency coronary artery bypass grafting (CABG) * stent implantation * intracoronary thrombolysis * anticoagulation with heparin or glycoprotein IIb/IIIa inhibitors * thrombus aspiration as reperfusion strategy * platelet P2Y12 receptor inhibitors: The CURE trial in 2001 determined that the addition of clopidogrel showed a positive effect on cardiovascular mortality, non-fatal MI, and stroke at the cost of an increased risk of major bleeding. To address the possibility of identifying and treating asymptomatic coronary artery disease to prevent development of<unk> , the COURAGE trial was published in 2018. It determined that preemptive treatment with percutaneous coronary intervention (PCI) did not lead to a difference in death or myocardial infarction over a 15-year period. There are numerous treatments currently being studied for management and prevention of<unk> . Statin drugs, in addition to their primary cholesterol-lowering mechanisms of action, have been studied to target a number of pathways that may decrease coronary inflammation and subsequent<unk> . Another realm of potential treatments in early stages of adoption is in therapeutic use of contrast ultrasound on thrombus dissolution.
Coronary thrombosis
Coronary occlusion
Coronary artery ectasia
Coronary artery aneurysm
Coronary ischemia
Cholesterol embolism
Vasculitis
Embolism